What Does Antidepressant Drug level Monitoring Reveal About Outpatient Treatment and Patient Adherence?

Abstract

Introduction The evaluation of plasma levels of antidepressants may improve the treatment outcome. The aim was to verify adherence and adequacy of administered doses of antidepressants among patients hospitalized for inadequate outpatient therapeutic response.

Methods Selective serotonin reuptake inhibitors or venlafaxine plasma levels were assessed on the first day of hospitalization and after 3 days of controlled administration. The patients were considered adherent if the plasma level on admission was within the interval of the minimum and maximum plasma level on the fourth day, expanded by 30%. The adequacy of antidepressant doses used during the outpatient treatment was assessed by comparing the plasma level on the fourth day with the therapeutic reference range.

Results Out of 83 patients, 52 (62.7%) were adherent. The plasma levels of antidepressants on the fourth day were found to be within the therapeutic reference range in 35 (43.2%) patients. The same number manifested levels below the therapeutic reference range. In 11 (13.6%) patients, the levels were higher than recommended. No significant difference in rate of adherence was found among individual antidepressants.

Conclusion The results show that antidepressant nonresponders are frequently under-dosed or nonadherent.

Key words

adherence - depression - antidepressants - plasma levels - therapeutic drug monitoring

• References

• 1 Hiemke C, Baumann P, Bergemann N. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
• 2 Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105: 164-172
• 3 Ostad Haji E, Tadić A, Wagner S. et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol. 2011; 31: 281-286
• 4 Charlier C, Pinto E, Ansseau M. et al. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol. 2002; 16: 369-372
• 5 Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet. 1987; 13: 381-392
• 6 Urinovska R, Brozmanova H, Sistik P. et al. Liquid chromatography – tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 907: 101-107
• 7 Krivoy A, Balicer RD, Fledman B. et al. The impact of age and gender on adherence to antidepressants: A 4-year population-based cohort study. Psychopharmacology 2015; 232: 3385-3390
• 8 Reis M, Akerblad AC, Ekselius L. et al. Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care. J Clin Psychopharmacol. 2010; 30: 746-748
• 9 Gex-Fabry M, Gervasoni N, Eap CB. et al. Time course of response to paroxetine: Influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 892-900
• 10 Gilles M, Deuschle M, Kellner S. et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005; 38: 118-121
• 11 Baumann P, Hiemke C, Ulrich S. et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
• 12 Haen E, Greiner C, Bader W. et al. Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 2008; 79: 558-566
• 13 Ostad Haji E, Mann K, Dragicevic A. et al. Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. Ther Drug Monit. 2013; 35: 396-401